J Korean Med Assoc.  2010 Feb;53(2):92-97.

Incidence, Epidemiology and Patterns of Progression of Prostate Cancer

• Kim SJ
• Kim SI

Abstract

Prostate cancer is the fourth most common cancer in men worldwide. Its incidence and mortality vary widely between countries and ethnicities. In Korea, the incidence of prostate cancer was much lower than that in most westernized countries, but recently, it appears to be rapidly increasing steadily. Prostate cancer has now become the fifth most common cancer in men in Korea since the year 2002. The recent dramatic increase in incidence may be attributed to the growth of elderly population, a westernized diet in daily life style, and introduction of prostate-specific antigen (PSA) screening. The prevalence of latent prostate cancers is similar around the world, but the incidence of clinically manifest cancers differs, with Asians having the lowest rates of clinical prostate cancers. Diet may play a role in converting latent prostate cancer into clinically manifest one. Fat consumption, especially polyunsaturated fat, shows a strong positive correlation with prostate cancer incidence and mortality. The mortality rates for prostate cancer have been decreasing in many developed countries, thanks to early detection and improved treatment, while the mortality rates have been increasing in Korea. Since a significantly higher proportion of Korean prostate cancers exhibit poor differentiation, early diagnosis and appropriate treatment may be important.

Keyword

Prostate cancer; Incidence; Mortality; Progression

MeSH Terms

Aged
Asian Continental Ancestry Group
Developed Countries
Diet
Early Diagnosis
Humans
Incidence
Korea
Life Style
Male
Mass Screening
Prevalence
Prostate
Prostate-Specific Antigen
Prostatic Neoplasms
Prostate-Specific Antigen

Reference

1. Klein EA, Platz EA, Thompson IM. Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, editors. Epidemiology, etiology, and prevention of prostate cancer. Campbell-Walsh urology. 2007. 9th ed. Philadelphia: Saunders;2854–2873.

2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009. 59:225–249.

3. Korea Central Cancer Registry, National Cancer Center. Cancer Statistics in Korea. http://www.ncc.re.kr.

4. Shin HR, Won YJ, Jung KW, Kong HJ, Yim SH, Lee JK, Noh HI, Lee JK, Pisani P, Park JG, Ahn YO, Lee SY, Lee CW, Woo ZH, Lee TY, Choi JS, Yoo CI, Bae JM. Nationwide cancer incidence in Korea, 1999-2001; first result using the national cancer incidence database. Cancer Res Treat. 2005. 37:325–331.

5. Shin HR, Jung KW, Won YJ, Kong HJ, Yim SH, Sung J, Seo SW, Kim KY, Lee SY, Kong IS, Hwang IK, Lee CW, Woo ZH, Lee TY, Choi JS, Yoo CI, Bae JM, Yoo KY. National cancer incidence for the year 2002 in Korea. Cancer Res Treat. 2007. 39:139. 149.

6. Won YJ, Sung J, Jung KW, Kong HJ, Park S, Shin HR, Park EC, Ahn YO, Hwang IK, Lee DH, Choi JS, Kim WC, Lee TY, Yoo CI, Bae JM, Kim ON, Chung W, Kong IS, Lee DH, Lee JS. Nationwide cancer incidence in Korea, 2003-2005. Cancer Res Treat. 2009. 41:122–131.

7. Park SK, Sakoda LC, Kang D, Chokkalingam AP, Lee E, Shin HR, Ahn YO, Shin MH, Lee CW, Lee DH, Blair A, Devesa SS, Hsing AW. Rising prostate cancer rates in South Korea. Prostate. 2006. 66:1285–1291.

8. The Korean Urological Association. Data on statistics of management in resident training hospital in the Korean Urological Association: 1984-2002. 2004. Seoul: Eui-hak Publishing & Printing Co.;18–19.

9. The Korean Urological Association. Data on statistics of management in resident training hospital in the Korean Urological Association in the year 2007. Korean J Urol. 2008. 49:1171–1172.

10. Sata F, Umemura T, Kishi R. The epidemiology of prostate cancer-recent trends in prostate cancer incidence and mortality. Gan To Kagaku Ryoho. 2001. 28:184–188.

11. Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA. 1995. 273:548–552.

12. Hankey BF, Feuer EJ, Clegg LX, Hayes RB, Legler JM, Prorok PC, Ries LA, Merrill RM, Kaplan RS. Cancer surveillance series: interpreting trends in prostate cancer-part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst. 1999. 91:1017–1024.

13. Sirovich BE, Schwartz LM, Woloshin S. Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence? JAMA. 2003. 289:1414–1420.

14. Crawford ED. Understanding the epidemiology, natural history, and key pathways involved in prostate cancer. Urology. 2009. 73:S 5A. 4–10.

15. Yin M, Bastacky S, Chandran U, Becich MJ, Dhir R. Prevalence of incidental prostate cancer in the general population: a study of healthy organ donors. J Urol. 2008. 179:892–895.

16. Presti JC Jr, Kane CJ, Shinohara K, Carroll PR. Tanagho EA, McAninch JW, editors. Neoplasms of the prostate gland. Smith's general urology. 2008. 17th ed. New York: McGraw-Hill;348–374.

17. Bostwick DG, Burke HB, Djakiew D, Euling S, Ho SM, Landolph J, Morrison H, Sonawane B, Shifflett T, Waters DJ, Timms B. Human prostate cancer risk factors. Cancer. 2004. 101:10 S. 2371–2490.

18. Carter HB, Piantadosi S, Isaacs JT. Clinical evidence for and implications of the multistep development of prostate cancer. J Urol. 1990. 143:742–746.

19. Hsing AW, Sakoda LC, Chua SC Jr. Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr. 2007. 86:S. 843S–857S.

20. Hsing AW, Devesa SS. Trends and patterns of prostate cancer: what do they suggest? Epidemiol Rev. 2001. 23:3–13.

21. Kim SC. A continuous increase in prevalence of prostate cancer in Korea and its causes. J Korean Med Assoc. 2004. 47:394–402.

22. Murphy GP, Natarajan N, Pontes JE, Schmitz RL, Smart CR, Schmidt JD, Mettlin C. The national survey of prostate cancer in the United States by the American College of Surgeons. J Urol. 1982. 127:928–934.

23. Mettlin C, Murphy GP, Babaian RJ, Chesley A, Kane RA, Littrup PJ, Mostofi FK, Ray PS, Shanberg AM, Toi A. The results of a five-year early prostate cancer detection intervention. Investigators of the American Cancer Society National Prostate Cancer Detection Project. Cancer. 1996. 77:150–159.

24. Paquette EL, Sun L, Paquette LR, Connelly R, McLeod DG, Moul JW. Improved prostate cancer-specific survival and other disease parameters: impact of prostate-specific antigen testing. Urology. 2002. 60:756–759.

25. Derweesh IH, Kupelian PA, Zippe C, Levin HS, Brainard J, Magi-Galluzzi C, Myles J, Reuther AM, Klein EA. Continuing trends in pathological stage migration in radical prostatectomy specimens. Urol Oncol. 2004. 22:300–306.

26. Song K, Song C, Ahn H. Continuing trends of the clinical parameter migration in patients with prostate cancer in Korea. Korean J Urol. 2007. 48:574–578.

27. Jung KW, Yim SH, Kong HJ, Hwang SY, Won YJ, Lee JK, Shin HR. Cancer survival in Korea 1993-2002: a population-based study. J Korean Med Sci. 2007. 22:S. S5–S10.

28. Welch HG, Schwartz LM, Woloshin S. Are increasing 5-year survival rates evidence of success against cancer? JAMA. 2000. 283:2975–2978.

29. Kessler B, Albertsen P. The natural history of prostate cancer. Urol Clin North Am. 2003. 30:219–226.

30. Gonzalgo ML, Isaacs WB. Molecular pathways to prostate cancer. J Urol. 2003. 170:2444–2452.

31. Barnes RW. Survival with conservative therapy. JAMA. 1969. 210:331–332.

32. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 1974. 111:58–64.

33. Chodak GW, Thisted RA, Gerber GS, Johansson JE, Adolfsson J, Jones GW, Chisholm GD, Moskovitz B, Livne PM, Warner J. Results of conservative management of clinically localized prostate cancer. N Engl J Med. 1994. 330:242–248.

34. Johansson JE, Andrén O, Andersson SO, Dickman PW, Holmberg L, Magnuson A, Adami HO. Natural history of early, localized prostate cancer. JAMA. 2004. 291:2713–2719.

35. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol. 2010. 28:126–131.

36. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999. 281:1591–1597.

37. Barocas DA, Cowan JE, Smith JA Jr, Carroll PR. CaPSURE Investigators. What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database? J Urol. 2008. 180:1330–1334.

38. Song C, Kang T, Lee MS, Ro JY, Lee SE, Lee E, Choi HY, Han DH, Hong SJ, Chung BH, Kim CS, Ahn H. Clinico-pathological characteristics of prostate cancer in Korean men and nomograms for the prediction of the pathological stage of the clinically localized prostate cancer: a multi-institutional update. Korean J Urol. 2007. 48:125–130.

39. Song SY, Kim SR, Ahn G, Choi HY. Pathologic characteristics of prostatic adenocarcinomas: a mapping analysis of Korean patients. Prostate Cancer Prostatic Dis. 2003. 6:143–147.